Key Takeaway: Cognition Therapeutics has launched an expanded access program for its experimental drug targeting dementia with Lewy bodies (DLB). This initiative is notably backed by a donation from the family of a trial participant, highlighting community support for the research. The program aims to offer potential treatment options for patients suffering from this condition.
Price reaction · baseline $0.314 (2025-06-10 close) · hit pre-market · 3 other CGTX headline(s) in the window, move may be shared
day 0 close · peak
+1%
Market Sentiment Analysis
POSITIVE FACTORS
Cognition Therapeutics initiates an expanded access program.
The program is supported by a donation from a trial participant's family.
This initiative may provide hope for patients with DLB.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
You are now leaving the Cognition Therapeutics website
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Frequently Asked Questions
What is the purpose of the expanded access program?
The program aims to provide potential treatment options for patients with DLB.
Who funded the expanded access program?
The program is funded by a donation from a trial participant's family.
What condition does the experimental drug target?
The drug targets dementia with Lewy bodies (DLB).
What is Cognition Therapeutics' role in this program?
Cognition Therapeutics is initiating and managing the expanded access program.